Reenie McCarthy, CEO
Developing mitochondrial targeted therapeutics to address the mitochondrial function associated with many rare genetic diseases, neurodegenerative diseases, and common diseases of aging. Their lead compound has been shown to improve mitochondrial structure and function across multiple disease models — improving ATP production, decreasing oxidative stress and reducing inflammation, fibrosis and cell death.
source
